

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C.**

---

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) **March 9, 2005**

**MIM Corporation**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**0-28740**  
(Commission  
File Number)

**05-0489664**  
(IRS Employer  
Identification No.)

**100 Clearbrook Road, Elmsford, New York**  
(Address of Principal Executive Offices)

**10523**  
(Zip Code)

Registrant's telephone number, including area code **(914) 460-1600**

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Section Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

---

**Item 8.01 Other Events.**

On March 9, 2005, we issued a joint press release with Chronimed Inc. announcing that at special stockholder meetings held earlier that day each company received the requisite approvals for our merger with Chronimed. Our shareholders also approved (i) an amendment of our certificate of incorporation to change our name to BioScrip, Inc. and to increase the number authorized shares of common stock available for issuance from 40 million to 75 million shares, and (iii) an increase in the number of shares of common stock reserved for issuance under our 2001 Incentive Stock Plan from 3.75 million to 5.75 million shares.

The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.

**Item 9.01 Financial Statements and Exhibits.**

(c) Exhibits. The following Exhibits are filed with this Report:

99.1 Joint Press Release of MIM Corporation and Chronimed Inc. dated March 9, 2005.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned duly authorized.

Date: March 9, 2005

MIM CORPORATION

By: /s/ Barry A. Posner  
Barry A. Posner,  
Executive Vice President, Secretary  
and General Counsel

## **MIM and Chronimed Shareholders Approve Merger**

### BioScrip to be one of Largest Specialty Pharmacies in US

**ELMSFORD, NY and MINNEAPOLIS, MN - March 9, 2005 - MIM Corporation (NASDAQ: MIMS) and Chronimed Inc. (NASDAQ: CHMD)** today announced that MIM and Chronimed obtained the requisite approvals for the merger of MIM and Chronimed at special shareholder meetings held earlier today.

The holders of Chronimed common stock will receive 1.12 shares of MIM Corporation common stock in the merger. Upon consummation of the merger, MIM and Chronimed become one company and will change its name to BioScrip, Inc. The combined company will trade on Nasdaq National Market under the symbol "BIOS".

MIM shareholders approved the issuance of its common stock to Chronimed's shareholders in connection with the merger, amended its certificate of incorporation to change MIM's name to "BioScrip, Inc.", increased its authorized shares of common stock from 40 million to 75 million shares and increased the number of shares reserved for issuance under its 2001 Incentive Stock Plan from 3.75 million to 5.75 million shares.

Richard H. Friedman, Chairman and Chief Executive Officer of MIM commented: "We are pleased to have shareholder support for the merger and look forward to executing our growth strategy. The combination of our highly complementary businesses will enable us to be more competitive in the national managed care arena."

Henry F. Blissenbach, Chairman and Chief Executive Officer of Chronimed stated, "This is a significant milestone for both companies. BioScrip will be one of the largest specialty pharmacy services companies in the United States. In MIM Corporation, we have found a partner that complements our vision of building a national leader in specialty pharmacy services, one community at a time."

#### **About MIM Corporation**

MIM Corporation ([www.mimcorporation.com](http://www.mimcorporation.com)) is a pharmaceutical healthcare organization delivering innovative pharmacy benefit and healthcare solutions that provide results beyond expectations. We excel by harnessing our clinical expertise, sophisticated data management, and therapeutic fulfillment capability, and combine it with our dedicated, responsive team of professionals that understands our partners' needs. The result is cost-effective solutions enhancing the quality of patient life.

#### **About Chronimed Inc.**

Chronimed Inc. is a specialty pharmacy that distributes prescription drugs and provides specialized therapy management services for people with certain conditions, including HIV/AIDS, organ transplants, and diseases treated with biotech injectable medications. Chronimed works with patients, physicians and other health care providers, pharmaceutical manufacturers, health plans and insurers, and government agencies to improve clinical and economic outcomes. Chronimed's web site address is [www.chronimed.com](http://www.chronimed.com)

#### **Forward Looking Statements**

This press release may contain statements which constitute forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the intent, belief or current expectations of the Company, its directors, or its officers with respect to the future operating performance of the Company. Investors are cautioned that any such forward looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward looking statements as a result of various factors. Important factors that could cause such differences are described in the Company's periodic filings with the Securities and Exchange Commission.

#### **Contacts:**

##### **MIM**

Barry A. Posner  
Executive Vice President  
MIM Corporation  
914-460-1638  
Email: [bposner@mimcorporation.com](mailto:bposner@mimcorporation.com)

Rachel Levine  
Investor Relations  
The Anne McBride Co.  
212-983-1702 ext. 207  
Email: [rlevine@annemcbride.com](mailto:rlevine@annemcbride.com)

##### **Chronimed**

Brad Schumacher  
Investor Relations  
Chronimed Inc.  
952-979-3942  
Email: [bschumacher@chronimed.com](mailto:bschumacher@chronimed.com)